Copyright Reports & Markets. All rights reserved.

Global Live Attenuated Influenza Vaccine (LAIV) Market Growth 2022-2028

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales 2017-2028
    • 2.1.2 World Current & Future Analysis for Live Attenuated Influenza Vaccine (LAIV) by Geographic Region, 2017, 2022 & 2028
    • 2.1.3 World Current & Future Analysis for Live Attenuated Influenza Vaccine (LAIV) by Country/Region, 2017, 2022 & 2028
  • 2.2 Live Attenuated Influenza Vaccine (LAIV) Segment by Type
    • 2.2.1 Trivalent Flu Vaccine
    • 2.2.2 Quadrivalent Flu Vaccine
  • 2.3 Live Attenuated Influenza Vaccine (LAIV) Sales by Type
    • 2.3.1 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Type (2017-2022)
    • 2.3.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue and Market Share by Type (2017-2022)
    • 2.3.3 Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Type (2017-2022)
  • 2.4 Live Attenuated Influenza Vaccine (LAIV) Segment by Application
    • 2.4.1 Hospital
    • 2.4.2 Clinic
    • 2.4.3 Public Health Agency
    • 2.4.4 Other
  • 2.5 Live Attenuated Influenza Vaccine (LAIV) Sales by Application
    • 2.5.1 Global Live Attenuated Influenza Vaccine (LAIV) Sale Market Share by Application (2017-2022)
    • 2.5.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue and Market Share by Application (2017-2022)
    • 2.5.3 Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Application (2017-2022)

3 Global Live Attenuated Influenza Vaccine (LAIV) by Company

  • 3.1 Global Live Attenuated Influenza Vaccine (LAIV) Breakdown Data by Company
    • 3.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales by Company (2020-2022)
    • 3.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Sales Market Share by Company (2020-2022)
  • 3.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue by Company (2020-2022)
    • 3.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Revenue by Company (2020-2022)
    • 3.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Revenue Market Share by Company (2020-2022)
  • 3.3 Global Live Attenuated Influenza Vaccine (LAIV) Sale Price by Company
  • 3.4 Key Manufacturers Live Attenuated Influenza Vaccine (LAIV) Producing Area Distribution, Sales Area, Product Type
    • 3.4.1 Key Manufacturers Live Attenuated Influenza Vaccine (LAIV) Product Location Distribution
    • 3.4.2 Players Live Attenuated Influenza Vaccine (LAIV) Products Offered
  • 3.5 Market Concentration Rate Analysis
    • 3.5.1 Competition Landscape Analysis
    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion

4 World Historic Review for Live Attenuated Influenza Vaccine (LAIV) by Geographic Region

  • 4.1 World Historic Live Attenuated Influenza Vaccine (LAIV) Market Size by Geographic Region (2017-2022)
    • 4.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales by Geographic Region (2017-2022)
    • 4.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue by Geographic Region
  • 4.2 World Historic Live Attenuated Influenza Vaccine (LAIV) Market Size by Country/Region (2017-2022)
    • 4.2.1 Global Live Attenuated Influenza Vaccine (LAIV) Annual Sales by Country/Region (2017-2022)
    • 4.2.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue by Country/Region
  • 4.3 Americas Live Attenuated Influenza Vaccine (LAIV) Sales Growth
  • 4.4 APAC Live Attenuated Influenza Vaccine (LAIV) Sales Growth
  • 4.5 Europe Live Attenuated Influenza Vaccine (LAIV) Sales Growth
  • 4.6 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales Growth

5 Americas

  • 5.1 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Country
    • 5.1.1 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022)
    • 5.1.2 Americas Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022)
  • 5.2 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Type
  • 5.3 Americas Live Attenuated Influenza Vaccine (LAIV) Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Region
    • 6.1.1 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Region (2017-2022)
    • 6.1.2 APAC Live Attenuated Influenza Vaccine (LAIV) Revenue by Region (2017-2022)
  • 6.2 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Type
  • 6.3 APAC Live Attenuated Influenza Vaccine (LAIV) Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan

7 Europe

  • 7.1 Europe Live Attenuated Influenza Vaccine (LAIV) by Country
    • 7.1.1 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022)
    • 7.1.2 Europe Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022)
  • 7.2 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Type
  • 7.3 Europe Live Attenuated Influenza Vaccine (LAIV) Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) by Country
    • 8.1.1 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Country (2017-2022)
    • 8.1.2 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Revenue by Country (2017-2022)
  • 8.2 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Type
  • 8.3 Middle East & Africa Live Attenuated Influenza Vaccine (LAIV) Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends

10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Live Attenuated Influenza Vaccine (LAIV)
  • 10.3 Manufacturing Process Analysis of Live Attenuated Influenza Vaccine (LAIV)
  • 10.4 Industry Chain Structure of Live Attenuated Influenza Vaccine (LAIV)

11 Marketing, Distributors and Customer

  • 11.1 Sales Channel
    • 11.1.1 Direct Channels
    • 11.1.2 Indirect Channels
  • 11.2 Live Attenuated Influenza Vaccine (LAIV) Distributors
  • 11.3 Live Attenuated Influenza Vaccine (LAIV) Customer

12 World Forecast Review for Live Attenuated Influenza Vaccine (LAIV) by Geographic Region

  • 12.1 Global Live Attenuated Influenza Vaccine (LAIV) Market Size Forecast by Region
    • 12.1.1 Global Live Attenuated Influenza Vaccine (LAIV) Forecast by Region (2023-2028)
    • 12.1.2 Global Live Attenuated Influenza Vaccine (LAIV) Annual Revenue Forecast by Region (2023-2028)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Live Attenuated Influenza Vaccine (LAIV) Forecast by Type
  • 12.7 Global Live Attenuated Influenza Vaccine (LAIV) Forecast by Application

13 Key Players Analysis

  • 13.1 Sanofi Pasteur
    • 13.1.1 Sanofi Pasteur Company Information
    • 13.1.2 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Product Offered
    • 13.1.3 Sanofi Pasteur Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.1.4 Sanofi Pasteur Main Business Overview
    • 13.1.5 Sanofi Pasteur Latest Developments
  • 13.2 AstraZeneca
    • 13.2.1 AstraZeneca Company Information
    • 13.2.2 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Product Offered
    • 13.2.3 AstraZeneca Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.2.4 AstraZeneca Main Business Overview
    • 13.2.5 AstraZeneca Latest Developments
  • 13.3 CSL
    • 13.3.1 CSL Company Information
    • 13.3.2 CSL Live Attenuated Influenza Vaccine (LAIV) Product Offered
    • 13.3.3 CSL Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.3.4 CSL Main Business Overview
    • 13.3.5 CSL Latest Developments
  • 13.4 Abbott
    • 13.4.1 Abbott Company Information
    • 13.4.2 Abbott Live Attenuated Influenza Vaccine (LAIV) Product Offered
    • 13.4.3 Abbott Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.4.4 Abbott Main Business Overview
    • 13.4.5 Abbott Latest Developments
  • 13.5 GlaxoSmithKline
    • 13.5.1 GlaxoSmithKline Company Information
    • 13.5.2 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Product Offered
    • 13.5.3 GlaxoSmithKline Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.5.4 GlaxoSmithKline Main Business Overview
    • 13.5.5 GlaxoSmithKline Latest Developments
  • 13.6 Serum Institute
    • 13.6.1 Serum Institute Company Information
    • 13.6.2 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Product Offered
    • 13.6.3 Serum Institute Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.6.4 Serum Institute Main Business Overview
    • 13.6.5 Serum Institute Latest Developments
  • 13.7 Fluenz Tetra
    • 13.7.1 Fluenz Tetra Company Information
    • 13.7.2 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Product Offered
    • 13.7.3 Fluenz Tetra Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.7.4 Fluenz Tetra Main Business Overview
    • 13.7.5 Fluenz Tetra Latest Developments
  • 13.8 Cytiva
    • 13.8.1 Cytiva Company Information
    • 13.8.2 Cytiva Live Attenuated Influenza Vaccine (LAIV) Product Offered
    • 13.8.3 Cytiva Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.8.4 Cytiva Main Business Overview
    • 13.8.5 Cytiva Latest Developments
  • 13.9 BioDiem
    • 13.9.1 BioDiem Company Information
    • 13.9.2 BioDiem Live Attenuated Influenza Vaccine (LAIV) Product Offered
    • 13.9.3 BioDiem Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.9.4 BioDiem Main Business Overview
    • 13.9.5 BioDiem Latest Developments
  • 13.10 FluMist
    • 13.10.1 FluMist Company Information
    • 13.10.2 FluMist Live Attenuated Influenza Vaccine (LAIV) Product Offered
    • 13.10.3 FluMist Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.10.4 FluMist Main Business Overview
    • 13.10.5 FluMist Latest Developments
  • 13.11 GSK
    • 13.11.1 GSK Company Information
    • 13.11.2 GSK Live Attenuated Influenza Vaccine (LAIV) Product Offered
    • 13.11.3 GSK Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.11.4 GSK Main Business Overview
    • 13.11.5 GSK Latest Developments
  • 13.12 ChangChun High & New Technology
    • 13.12.1 ChangChun High & New Technology Company Information
    • 13.12.2 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Product Offered
    • 13.12.3 ChangChun High & New Technology Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.12.4 ChangChun High & New Technology Main Business Overview
    • 13.12.5 ChangChun High & New Technology Latest Developments
  • 13.13 BCHT Biotechnology
    • 13.13.1 BCHT Biotechnology Company Information
    • 13.13.2 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Product Offered
    • 13.13.3 BCHT Biotechnology Live Attenuated Influenza Vaccine (LAIV) Sales, Revenue, Price and Gross Margin (2020-2022)
    • 13.13.4 BCHT Biotechnology Main Business Overview
    • 13.13.5 BCHT Biotechnology Latest Developments

14 Research Findings and Conclusion

The global market for Live Attenuated Influenza Vaccine (LAIV) is estimated to increase from US$ million in 2021 to reach US$ million by 2028, exhibiting a CAGR of % during 2022-2028. Keeping in mind the uncertainties of COVID-19 and Russia-Ukraine War, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

The APAC Live Attenuated Influenza Vaccine (LAIV) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The United States Live Attenuated Influenza Vaccine (LAIV) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The Europe Live Attenuated Influenza Vaccine (LAIV) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

The China Live Attenuated Influenza Vaccine (LAIV) market is expected at value of US$ million in 2022 and grow at approximately % CAGR during 2022 and 2028.

Global key Live Attenuated Influenza Vaccine (LAIV) players cover Sanofi Pasteur, AstraZeneca, CSL, Abbott and GlaxoSmithKline, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

Report Coverage
This latest report provides a deep insight into the global Live Attenuated Influenza Vaccine (LAIV) market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, value chain analysis, etc.

This report aims to provide a comprehensive picture of the global Live Attenuated Influenza Vaccine (LAIV) market, with both quantitative and qualitative data, to help readers understand how the Live Attenuated Influenza Vaccine (LAIV) market scenario changed across the globe during the pandemic and Russia-Ukraine War.

The base year considered for analyses is 2021, while the market estimates and forecasts are given from 2022 to 2028. The market estimates are provided in terms of revenue in USD millions and volume in K Units.

Market Segmentation:
The study segments the Live Attenuated Influenza Vaccine (LAIV) market and forecasts the market size by Type (Trivalent Flu Vaccine and Quadrivalent Flu Vaccine,), by Application (Hospital, Clinic, Public Health Agency and Other), and region (APAC, Americas, Europe, and Middle East & Africa).

Segmentation by type
Trivalent Flu Vaccine
Quadrivalent Flu Vaccine

Segmentation by application
Hospital
Clinic
Public Health Agency
Other

Segmentation by region
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Major companies covered
Sanofi Pasteur
AstraZeneca
CSL
Abbott
GlaxoSmithKline
Serum Institute
Fluenz Tetra
Cytiva
BioDiem
FluMist
GSK
ChangChun High & New Technology
BCHT Biotechnology

Chapter Introduction
Chapter 1: Scope of Live Attenuated Influenza Vaccine (LAIV), Research Methodology, etc.
Chapter 2: Executive Summary, global Live Attenuated Influenza Vaccine (LAIV) market size (sales and revenue) and CAGR, Live Attenuated Influenza Vaccine (LAIV) market size by region, by type, by application, historical data from 2017 to 2022, and forecast to 2028.
Chapter 3: Live Attenuated Influenza Vaccine (LAIV) sales, revenue, average price, global market share, and industry ranking by company, 2017-2022
Chapter 4: Global Live Attenuated Influenza Vaccine (LAIV) sales and revenue by region and by country. Country specific data and market value analysis for the U.S., Canada, Europe, China, Japan, South Korea, Southeast Asia, India, Latin America and Middle East & Africa.
Chapter 5, 6, 7, 8: Americas, APAC, Europe, Middle East & Africa, sales segment by country, by type, and type.
Chapter 9: Analysis of the current market trends, market forecast, opportunities and economic trends that are affecting the future marketplace
Chapter 10: Manufacturing cost structure analysis
Chapter 11: Sales channel, distributors, and customers
Chapter 12: Global Live Attenuated Influenza Vaccine (LAIV) market size forecast by region, by country, by type, and application.
Chapter 13: Comprehensive company profiles of the leading players, including Sanofi Pasteur, AstraZeneca, CSL, Abbott, GlaxoSmithKline, Serum Institute, Fluenz Tetra, Cytiva and BioDiem, etc.
Chapter 14: Research Findings and Conclusion

Buy now